Literature DB >> 24702820

18F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons.

David S Knopman1, Clifford R Jack2, Heather J Wiste3, Emily S Lundt3, Stephen D Weigand3, Prashanthi Vemuri4, Val J Lowe5, Kejal Kantarci5, Jeffrey L Gunter5, Matthew L Senjem5, Michelle M Mielke6, Rosebud O Roberts7, Bradley F Boeve8, Ronald C Petersen9.   

Abstract

Our objective was to examine associations between glucose metabolism, as measured by (18)F-fluorodeoxyglucose positron emission tomography (FDG PET), and age and to evaluate the impact of carriage of an apolipoprotein E (APOE) ε4 allele on glucose metabolism and on the associations between glucose metabolism and age. We studied 806 cognitively normal (CN) and 70 amyloid-imaging-positive cognitively impaired participants (35 with mild cognitive impairment and 35 with Alzheimer's disease [AD] dementia) from the Mayo Clinic Study of Aging, Mayo Alzheimer's Disease Research Center and an ancillary study who had undergone structural MRI, FDG PET, and (11)C-Pittsburgh compound B (PiB) PET. Using partial volume corrected and uncorrected FDG PET glucose uptake ratios, we evaluated associations of regional FDG ratios with age and carriage of an APOE ε4 allele in CN participants between the ages of 30 and 95 years, and compared those findings with the cognitively impaired participants. In region-of-interest (ROI) analyses, we found modest but statistically significant declines in FDG ratio in most cortical and subcortical regions as a function of age. We also found a main effect of APOE ε4 genotype on FDG ratio, with greater uptake in ε4 noncarriers compared with carriers but only in the posterior cingulate and/or precuneus, lateral parietal, and AD-signature meta-ROI. The latter consisted of voxels from posterior cingulate and/or precuneus, lateral parietal, and inferior temporal. In age- and sex-matched CN participants the magnitude of the difference in partial volume corrected FDG ratio in the AD-signature meta-ROI for APOE ε4 carriers compared with noncarriers was about 4 times smaller than the magnitude of the difference between age- and sex-matched elderly APOE ε4 carrier CN compared with AD dementia participants. In an analysis in participants older than 70 years (31.3% of whom had elevated PiB), there was no interaction between PiB status and APOE ε4 genotype with respect to glucose metabolism. Glucose metabolism declines with age in many brain regions. Carriage of an APOE ε4 allele was associated with reductions in FDG ratio in the posterior cingulate and/or precuneus, lateral parietal, and AD-signature ROIs, and there was no interaction between age and APOE ε4 status. The posterior cingulate and/or precuneus and lateral parietal regions have a unique vulnerability to reductions in glucose metabolic rate as a function both of age and carriage of an APOE ε4 allele.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Aging; Alzheimer's disease; Apolipoprotein E; FDG positron emission tomography

Mesh:

Substances:

Year:  2014        PMID: 24702820      PMCID: PMC4053507          DOI: 10.1016/j.neurobiolaging.2014.03.006

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  57 in total

1.  Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis.

Authors:  Brian J Lopresti; William E Klunk; Chester A Mathis; Jessica A Hoge; Scott K Ziolko; Xueling Lu; Carolyn C Meltzer; Kurt Schimmel; Nicholas D Tsopelas; Steven T DeKosky; Julie C Price
Journal:  J Nucl Med       Date:  2005-12       Impact factor: 10.057

2.  Direct voxel-based comparison between grey matter hypometabolism and atrophy in Alzheimer's disease.

Authors:  G Chételat; B Desgranges; B Landeau; F Mézenge; J B Poline; V de la Sayette; F Viader; F Eustache; J-C Baron
Journal:  Brain       Date:  2007-12-05       Impact factor: 13.501

3.  Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI.

Authors:  J E Hixson; D T Vernier
Journal:  J Lipid Res       Date:  1990-03       Impact factor: 5.922

4.  Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease.

Authors:  S Minoshima; B Giordani; S Berent; K A Frey; N L Foster; D E Kuhl
Journal:  Ann Neurol       Date:  1997-07       Impact factor: 10.422

5.  Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B.

Authors:  Julie C Price; William E Klunk; Brian J Lopresti; Xueling Lu; Jessica A Hoge; Scott K Ziolko; Daniel P Holt; Carolyn C Meltzer; Steven T DeKosky; Chester A Mathis
Journal:  J Cereb Blood Flow Metab       Date:  2005-11       Impact factor: 6.200

Review 6.  Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD.

Authors:  Lisa Mosconi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-04       Impact factor: 9.236

7.  Brain FDG PET study of normal aging in Japanese: effect of atrophy correction.

Authors:  Daisuke Yanase; Ichiro Matsunari; Kazuyoshi Yajima; Weiping Chen; Akihiko Fujikawa; Shintaro Nishimura; Hiroshi Matsuda; Masahito Yamada
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-03-10       Impact factor: 9.236

8.  Regional cerebral function determined by FDG-PET in healthy volunteers: normal patterns and changes with age.

Authors:  A Loessner; A Alavi; K U Lewandrowski; D Mozley; E Souder; R E Gur
Journal:  J Nucl Med       Date:  1995-07       Impact factor: 10.057

9.  Imaging beta-amyloid burden in aging and dementia.

Authors:  C C Rowe; S Ng; U Ackermann; S J Gong; K Pike; G Savage; T F Cowie; K L Dickinson; P Maruff; D Darby; C Smith; M Woodward; J Merory; H Tochon-Danguy; G O'Keefe; W E Klunk; C A Mathis; J C Price; C L Masters; V L Villemagne
Journal:  Neurology       Date:  2007-05-15       Impact factor: 9.910

10.  11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment.

Authors:  Clifford R Jack; Val J Lowe; Matthew L Senjem; Stephen D Weigand; Bradley J Kemp; Maria M Shiung; David S Knopman; Bradley F Boeve; William E Klunk; Chester A Mathis; Ronald C Petersen
Journal:  Brain       Date:  2008-02-07       Impact factor: 13.501

View more
  46 in total

1.  Mapping 3-year changes in gray matter and metabolism in Aβ-positive nondemented subjects.

Authors:  Miguel Ángel Araque Caballero; Matthias Brendel; Andreas Delker; Jinyi Ren; Axel Rominger; Peter Bartenstein; Martin Dichgans; Michael W Weiner; Michael Ewers
Journal:  Neurobiol Aging       Date:  2015-08-18       Impact factor: 4.673

Review 2.  FDG-PET Contributions to the Pathophysiology of Memory Impairment.

Authors:  Shailendra Segobin; Renaud La Joie; Ludivine Ritz; Hélène Beaunieux; Béatrice Desgranges; Gaël Chételat; Anne Lise Pitel; Francis Eustache
Journal:  Neuropsychol Rev       Date:  2015-08-30       Impact factor: 7.444

3.  Rhinal hypometabolism on FDG PET in healthy APO-E4 carriers: impact on memory function and metabolic networks.

Authors:  Mira Didic; Olivier Felician; Natalina Gour; Rafaelle Bernard; Christophe Pécheux; Olivier Mundler; Mathieu Ceccaldi; Eric Guedj
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-04-22       Impact factor: 9.236

4.  Different partial volume correction methods lead to different conclusions: An (18)F-FDG-PET study of aging.

Authors:  Douglas N Greve; David H Salat; Spencer L Bowen; David Izquierdo-Garcia; Aaron P Schultz; Ciprian Catana; J Alex Becker; Claus Svarer; Gitte M Knudsen; Reisa A Sperling; Keith A Johnson
Journal:  Neuroimage       Date:  2016-02-23       Impact factor: 6.556

5.  Healthy brain ageing assessed with 18F-FDG PET and age-dependent recovery factors after partial volume effect correction.

Authors:  Stijn Bonte; Pieter Vandemaele; Stijn Verleden; Kurt Audenaert; Karel Deblaere; Ingeborg Goethals; Roel Van Holen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-11-23       Impact factor: 9.236

6.  Spatially Adaptive Varying Correlation Analysis for Multimodal Neuroimaging Data.

Authors:  Lexin Li; Jian Kang; Samuel N Lockhart; Jenna Adams; William J Jagust
Journal:  IEEE Trans Med Imaging       Date:  2018-07-18       Impact factor: 10.048

7.  Alzheimer Disease Signature Neurodegeneration and APOE Genotype in Mild Cognitive Impairment With Suspected Non-Alzheimer Disease Pathophysiology.

Authors:  Stefanie Schreiber; Frank Schreiber; Samuel N Lockhart; Andy Horng; Alexandre Bejanin; Susan M Landau; William J Jagust
Journal:  JAMA Neurol       Date:  2017-06-01       Impact factor: 18.302

Review 8.  Diagnostic utility of 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) in asymptomatic subjects at increased risk for Alzheimer's disease.

Authors:  Alexander Drzezga; Daniele Altomare; Cristina Festari; Javier Arbizu; Stefania Orini; Karl Herholz; Peter Nestor; Federica Agosta; Femke Bouwman; Flavio Nobili; Zuzana Walker; Giovanni Battista Frisoni; Marina Boccardi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-05-13       Impact factor: 9.236

9.  Dynamic relationships between age, amyloid-β deposition, and glucose metabolism link to the regional vulnerability to Alzheimer's disease.

Authors:  Hwamee Oh; Cindee Madison; Suzanne Baker; Gil Rabinovici; William Jagust
Journal:  Brain       Date:  2016-05-13       Impact factor: 13.501

Review 10.  Is amyloid-β harmful to the brain? Insights from human imaging studies.

Authors:  William Jagust
Journal:  Brain       Date:  2015-11-27       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.